ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义
Expression and prognostic significance of ERCC1,RRM1,and BRCA1mRNA in non-small cell lung cancer
摘 要
目的:探讨DNA修复基因家族成员ERCC1、RRM1和BRCA1在非小细胞肺癌(NSCLC)中的表达及预后意义。方法:应用实时荧光定量PCR技术对32例肺癌及16例癌旁组织中ERCC1、RRM1和BRCA1基因的mRNA进行定量检测。用非参数检验、相关分析、Kaplan-Meier生存曲线和COX多因素回归分析进行统计分析。结果:NSCLC中ERCC1、RRM1和BRCA1在癌组织内表达量显著高于癌旁组织,且在癌内表达具有正相关性;RRM1在肺鳞癌中高于腺癌,但在不同分期中表达无差异;ERCC1和BRCA1在不同病理类型和分期中表达均无差异;RRM1和BRCA1高表达组的生存期明显长于低表达组;COX多因素回归分析示RRM1表达是影响本组患者预后的独立因素。结论:NSCLC中,ERCC1、RRM1和BRCA1在肺癌组织中的表达显著高于癌旁组织,RRM1和BRCA1高表达组的生存期长于低表达组。RRM1和BRCA1可作为判断预后的一种指标。
DNA修复酶类
基因表达
预后
ERCC1
基因,RRM1,BRCA1
Carcinoma,non-small cell lung
DNA repair enzymes
Gene expression
Prognosis
ERCC1,RRM1,BRCA1
Abstract
Objective:To investigated the expressions of ERCC1,RRM1 and BRCA1(members of DNA repair gene family) in patients with non-small cell lung cancer(NSCLC) as well as their clinical prognostic significance.Methods:Expression levels of ERCC1,RRM1 and BRCA1 were detected by real-time PCR method in 32 NSCLC patients and 16 cases of adjacent normal lung tissues.Wilcoxon signed-rank test,Wilcoxon rank sum test,rank correlation,Kaplan-Meier survival curve,and COX multivariate regression analysis were used for statistical analysis.Results:The expression levels of ERCC1,RRM1 and BRCA1 were significantly higher in lung cancer tissues than that in adjacent normal lung tissues.There were significant correlations between intratumoral expression of ERCC1,RRM1,and BRCA1.RRM1 expression level was significantly higher in lung squamous cell carcinomas compared with lung adenocarcinomas but had no difference between different clinical stages.The expression of ERCC1 and BRCA1 had no difference between different pathological classification and clinical TNM stages.The patients with high expression of RRM1 and BRCA1 had significant longer survival time than those with low expression of RRM1 and BRCA1.COX multivariate regression analysis showed that expression of RRM1 was an independent prognostic factor for NSCLC.Conclusion:The expression levels of ERCC1,RRM1,and BRCA1 are significantly higher in lung cancer tissues than that of adjacent normal lung tissues.The patients with high expression of RRM1 and BRCA1 had significant longer survival time than those with low expression of RRM1 and BRCA1.RRM1 and BRCA1 mRNA expressions can be used to predict prognosis of NSCLC.
中图分类号 R734.2
所属栏目 临床研究
基金项目 上海市科委重大项目基金资助(编号:06DZ19502)
收稿日期 2007/4/20
修改稿日期 2007/6/20
网络出版日期
作者单位点击查看
备注陈芹(1977-),女(汉族),医学硕士,住院医师
引用该论文: CHEN Qin,ZHOU Cai-cun,ZHANG Jie. Expression and prognostic significance of ERCC1,RRM1,and BRCA1mRNA in non-small cell lung cancer[J]. Tumor, 2007, 27(9): 719～722
陈芹,周彩存,张颉. ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J]. 肿瘤, 2007, 27(9): 719～722
被引情况:
【1】姚传山,马磊,刘瑞青,李醒亚, "Ⅰ～Ⅲ期肺腺癌组织中EGFR基因突变与ERCC1和RRM1蛋白表达的关系",肿瘤 33, 258-263(2013)
共有人对该论文发表了看法，其中：
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
参考文献
【1】MOUNTAIN C F. Revisions in the International system for staging lung cancer[J].Chest,1997,111(6):1710-1717.
【2】MOUNTAIN CF,DRESLER CM. Regional lymph node classification for lung cancer staging[J].Chest,1997,111(6):1718-1723.
【3】SIMON G R,SHARMA S,CANTOR A,et al. ERCCl expression is a predictor of survival in resected patients with non-small cell lung cancer[J].Chest,2005,127(3):978-983.
【4】DE LAAt W L,JASPERS NG,HOEIJMAKERS JH. Molecular mechanism of nueleotide excision repair[J].Cenes Dev,1999,13(7):768-785.
【5】ROSELL R,COBO M,ISLA D,et al. Phannscogenomics and gemcitabine[J].Ann Oncol,2006,17(5):13-16.
【6】TARON M,ROSELL R,FELIP E,et al. BRCAI mRNA expmssion levels as an indicator of chemoresistance in lung caner[J].Hum Mol Genet,2004,13(20):2443-2449.
【7】LORD R V,BRABENDER J,GANDARA D,et al. Low ERCCI expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung Cancer[J].Clin Cancer Res,2002,8(7):2286-2291.
【8】DAVIDSON J D,MA L,FLAGELLA M,et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines[J].Cancer Res,2004,64(11):3761-3766.
【9】ROSELL R,DANENBERG K D,ALBEROLA V,et al. Ribonuclcotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2004,10(4):1318-1325.
【2】MOUNTAIN CF,DRESLER CM. Regional lymph node classification for lung cancer staging[J].Chest,1997,111(6):1718-1723.
【3】SIMON G R,SHARMA S,CANTOR A,et al. ERCCl expression is a predictor of survival in resected patients with non-small cell lung cancer[J].Chest,2005,127(3):978-983.
【4】DE LAAt W L,JASPERS NG,HOEIJMAKERS JH. Molecular mechanism of nueleotide excision repair[J].Cenes Dev,1999,13(7):768-785.
【5】ROSELL R,COBO M,ISLA D,et al. Phannscogenomics and gemcitabine[J].Ann Oncol,2006,17(5):13-16.
【6】TARON M,ROSELL R,FELIP E,et al. BRCAI mRNA expmssion levels as an indicator of chemoresistance in lung caner[J].Hum Mol Genet,2004,13(20):2443-2449.
【7】LORD R V,BRABENDER J,GANDARA D,et al. Low ERCCI expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung Cancer[J].Clin Cancer Res,2002,8(7):2286-2291.
【8】DAVIDSON J D,MA L,FLAGELLA M,et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines[J].Cancer Res,2004,64(11):3761-3766.
【9】ROSELL R,DANENBERG K D,ALBEROLA V,et al. Ribonuclcotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2004,10(4):1318-1325.
相关信息
